Xarelto Drug Lawsuits See Changes in Filings

It’s not uncommon for drugs that are available on the market to cause harm to the public. Advertisements  xarelto lawsuitspromote the positive aspects of these drugs; however, there are often serious side effects that can endanger consumers. Xarelto, the drug advertised to treat and prevent blood clots, has been involved in controversy due to its link to the risk of fatal internal bleeding and brain hemorrhage.

The Xarelto Case and Recent Updates

It’s alleged that Xarelto, marketed as a safe alternative to wayfarin and other blood thinners, has been found to cause serious and life-threatening problems such as internal bleeding and brain hemorrhages. Additionally, a clinical safety trial for Xarelto (called ROCKET-AF) showed that the device used during the trial to test for blood clotting had been recalled in December 2014. This recall occurred because the device was giving false (low) results.

There have been over 5,000 complaints and hundreds of lawsuits filed against Bayer and Johnson & Johnson. Those filing the lawsuits claimed that Xarelto (rivaroxaban) caused their uncontrolled bleeding. In a recent update to the Xarelto case, a federal judge overseeing the litigation issued a pre-trial order that changed the way the cases against the manufacturer can be filed.

As of May 20, 2016, the federal court is no longer accepting multiple case filings. This means, every case must be an individual filing. In the past, plaintiffs could file together because they all alleged the same problem—Xarelto caused them critical harm. Additionally, there are important deadlines that apply to those who were hurt after using Xarelto. The attorneys at Holton Law are available to explain the complexities involved with these deadlines and how they might impact your specific case.  

If you or someone you love suffered complications or injuries you believe were caused by Xarelto, contact the Holton Law Firm at 888-443-4387 to discuss your individual case.

 

Be the first to comment!
Post a Comment